RxDoctor Payments Data

John Whittaker, MD

Family Medicine · Pocomoke City, MDNPI 1548220692

Payments from drug & device makers

$2,634in general payments, 2019–2025

Across 78 payments — averaging $33.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$978
  • AbbVie$830
  • Novo Nordisk$174
  • Lilly USA, LLC$152
  • Biotronik Inc.$147
  • GSK$106
  • plus $247 from 10 others

What the payments were for

  • Food & beverage$2,61999%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,634 in reported general payments places this provider in the 80th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$101,832
Medicare patients
295
Services billed
927

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide74$86,670
EliquisApixaban67$75,007
JardianceEmpagliflozin32$45,992
XareltoRivaroxaban33$38,007
FarxigaDapagliflozin Propanediol36$37,362
TrulicityDulaglutide17$28,253
JanuviaSitagliptin Phosphate34$26,664
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$16,975
TradjentaLinagliptin13$12,253
Advair HfaFluticasone Propion/Salmeterol12$12,141
LinzessLinaclotide17$9,818
MovantikNaloxegol Oxalate11$6,748
MyrbetriqMirabegron11$6,279
Rosuvastatin Calcium131$4,679
SymbicortBudesonide/Formoterol Fumarate11$4,504

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$174$86,67074 claims
PfizerEliquis, Paxlovid$14$77,76882 claims
Boehringer IngelheimJardiance, Tradjenta$92$58,24545 claims
AstraZenecaFarxiga, Symbicort$978$41,86647 claims
Lilly USA, LLCTrulicity$152$28,25317 claims
GSKTrelegy Ellipta$106$16,97526 claims
AbbVieLinzess$830$9,81817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Pocomoke City

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →